Roche has launched its first infectious disease tests that run on the new molecular Cobas 5800 laboratory system in countries accepting the CE Mark.
The following Cobas tests can run on the new compact system:
- HIV-1
- Hepatitis B virus
- Hepatitis C virus
- HIV-1/HIV-2 qualitative
- Omni utility channel kit
The Cobas 5800 system offers the same menu as the Cobas 6800 and 8800 systems. Additionally, Roche is pursuing CE Mark approval for continued menu expansion on the Cobas 5800 system, including Cobas SARS-CoV-2, through early to mid-2022. Roche anticipates tests to be available beyond markets that accept the CE Mark in 2022.